ArticleJournal of the American Heart Association2026
Minimally Invasive, Echocardiography-Guided Mouse Model of Degenerative Mitral Regurgitation Recapitulates Cardiac Remodeling and Arrhythmogenesis.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDegenerative mitral regurgitation (MR) is a progressive valvular disorder that causes atrial enlargement, cardiac remodeling, heart failure, and arrhythmias. Current rodent models are limited by thoracotomy or intubation, which increase procedural risk and reduce reproducibility. METHODS AND
resultsWe established a minimally invasive, transthoracic echocardiography-guided mouse model of MR by puncturing the anterior mitral leaflet with a 27G needle introduced through the left ventricular apex. Ten-week-old C57BL/6J mice underwent baseline imaging before MR induction, and sham controls received apical puncture without leaflet disruption. Color Doppler confirmed regurgitant jets and increased vena contracta width, with procedural survival exceeding 90%. At 2 weeks, MR mice exhibited significant left heart enlargement, reduced fractional shortening, and myocardial fibrosis compared with sham. Pressure-volume loop analysis demonstrated increased end-diastolic volume and reduced compliance. RNA sequencing of left atrial tissues revealed enrichment of calcium signaling, apoptosis, and shear stress pathways. Histology confirmed increased cardiomyocyte apoptosis, accompanied by Connexin-43 downregulation and elevated ryanodine receptor 2 phosphorylation. Programmed atrial pacing induced atrial fibrillation in MR mice, consistent with enhanced arrhythmogenicity and calcium-handling abnormalities.
conclusionsThis closed-chest, echo-guided murine model reliably induces MR, avoids thoracotomy, and recapitulates key features of human disease, including chamber dilation, fibrosis, and arrhythmia susceptibility. It provides a scalable platform for mechanistic studies, genetic interventions, and drug testing in valvular heart disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.